Biocytogen Enters into Antibody Agreement with Merck KGaA Darmstadt Germany
Biocytogen Pharmaceuticals announced that it has entered into an evaluation and option agreement with Merck KGaA, Darmstadt, Germany to grant them a sole license to evaluate Biocytogen's proprietary antibodies against at least three distinct targets with an option to acquire some of the assets at a later date for therapeutic product development for all uses worldwide. Under the agreement, Biocytogen will provide Merck KGaA, Darmstadt, Germany antibodies directed against at least three targets specified by them from Biocytogen's Project Integrum (also called HiTS Platform), which are generated by leveraging Biocytogen's proprietary RenMice
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
